Sigyn Therapeutics (SIGY) CEO Note: Overcoming the Limitations of Previous Cytokine Storm Treatment Strategies
SAN DIEGO, Jan. 12, 2021 via
NewMediaWire Sigyn Therapeutics, Inc. (OTCMarkets: SIGY), today released the following note authored by its Chairman and CEO, Jim Joyce.
Dear Current and Candidate Shareholders,
We created Sigyn Therapy to address a significant unmet need in global health; the treatment of life-threatening inflammatory conditions that are precipitated by Cytokine Storm Syndrome (the Cytokine Storm). An annual market opportunity that exceeds $20 billion.
Based on our cumulative experience in developing first-in-industry medical technologies, we designed Sigyn Therapy to overcome the limitations of previous strategies to treat cytokine storm related conditions, yet still optimize patient safety and support widespread deployment.